PREF-NET: Patient Preference for Somatuline® Autogel Treatment Setting
Research type
Research Study
Full title
A cross-sectional patient-reported study to assess the patient preference of treatment administration setting, impact on health-related quality of life, work productivity, wider societal cost and healthcare utilisation for patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) prescribed Somatuline® Autogel® (lanreotide) in a homecare and hospital setting.
IRAS ID
286528
Contact name
Mohid Khan
Contact email
Sponsor organisation
IPSEN
Duration of Study in the UK
0 years, 7 months, 2 days
Research summary
This is a UK cross-sectional study which aims to assess patient preference for the treatment administration setting and the impact of the treatment setting on other areas of patients’ lives when taking Somatuline® Autogel® (which contains lanreotide). Currently, the patient-reported benefits of Somatuline® Autogel® and the associated homecare scheme have been based on personal accounts but this study will assess patient experience in an objective and methodological way. The study will collect quantitative data to describe patient experience and wider societal costs via an online survey. Additionally, a one-to-one interview will be used to collect qualitative data and describe patient experience in more depth.
The population for this study are adult patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) who were prescribed Somatuline® Autogel®. It is expected to recruit approx. 100 patients in total from five clinical sites.
It is anticipated that the study approval, site initiation, recruitment of, and data collection from patients will take approximately 6 to 7 months.REC name
East of Scotland Research Ethics Service REC 1
REC reference
21/ES/0021
Date of REC Opinion
15 Mar 2021
REC opinion
Further Information Favourable Opinion